enalapril / Generic mfg. - LARVOL DELTA

Progress in Anti-ageing Drug Research for Age-related Diseases: A Review. (PubMed, Ageing Res Rev) - "This review explores the anti-ageing potential of nine repurposed drugs: aspirin, atorvastatin, enalapril, metformin, canagliflozin, liraglutide, acarbose, N-acetylcysteine and dasatinib (commonly combined with quercetin). Specifically, it focuses on their mechanisms through the mechanistic target of rapamycin, adenosine monophosphate-activated protein kinase, nuclear factor kappa B and senescence-associated secretory phenotype pathways...This review synthesises progress and obstacles in transitioning drug development from targeting individual age-related diseases to addressing ageing as a unified biological process. Ultimately, the goal is to support a paradigm shift where ageing is recognised as a modifiable condition, enabling longer healthy human lifespans."

Journal • Review • Inflammation • mTOR

Chlorogenic acid-rich Morus alba leaf alleviated renal fibrosis through the regulation of transforming growth factor-beta 1 (TGF-β1) and fibroblast growth factor-2 (FGF-2), and extracellular matrix deposition. (PubMed, Mol Biol Rep) - "These findings suggest that MLE and CGA effectively alleviate renal fibrosis by modulating crucial profibrotic signaling pathways, presenting them as promising natural therapeutic alternatives for CKD-associated fibrosis."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • CTNNB1 • FGF2 • FGFR2 • SMAD3 • TGFB1 • TGFBR1

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. (PubMed, JAMA) - P4 | "In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group. ClinicalTrials.gov Identifier: NCT04023227."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Research Summary. (PubMed, JAMA) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Availability and Affordability of Essential Antihypertensive Medicines in Public and Private Primary Care Drug Facilities in a 4th Class Municipality in the Philippines. (PubMed, Acta Med Philipp) - "While most medicines were deemed affordable in the private setting, there are still drugs such as carvedilol and enalapril, that need to be regulated. There is a need to strengthen the local pharmaceutical subsystem because it is essential to ensure safe, effective, and quality medicines in the local health system through adequate mobilization of resources."

Journal

Multisystem Complications and Therapeutic Trends in Scleroderma Renal Crisis: Insight from a Five-Year Retrospective Cohort Study (KIDNEY WEEK 2025) - "Renal: Acute renal failure in 12.0% ESRD in 2.8%, renal transplant in 0.7%, Hemodilaysis in 2.1%, Cardiovascular: NSTEMI in 2.8%, STEMI in 0.8%, Neurological: Stroke in 2.3%, Pulmonary: Edema in 2.4%, Pulmonary Hypertension in 16.8%, Pulmonary fibrosis in 7.3%, Treatment: Antihypertensives: ACEi (Captopril in 2.4%, enalapril in 1.2%, and ARBs: Losartan in 5.6%, valsartan in 2.4%). Immune suppressants: Hydroxychloroquine (HCQ) in 7.9%, methotrexate (MTX) in 3.7%, mycophenolate in 12.7%, rituximab in 4.1%, prednisone in 18.4%, methylprednisone in 18.3% of the cohort...Low utilization of ACEi and ARBs indicates potential therapeutic gaps. Further research to refine treatment strategies is essential to improve mortality and patient outcomes."

Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Hypertension • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Bioinformatics-based identification of RAS disequilibrium involved in post-hemorrhagic shock mesenteric lymph return-mediated acute kidney injury in mice. (PubMed, PeerJ) - "Subsequently, male C57BL/6 mice subjected to hemorrhagic shock were treated with the angiotensin converting enzyme (ACE) inhibitor enalapril, angiotensin (1-7) (Ang (1-7)), and angiotensin II (Ang II) type 1 receptor (AT1R) inhibitor losartan. Conversely, the beneficial role of MLDL was abolished by Ace2 deficiency and the administration of Ang II and A-779. Collectively, these findings indicate that disequilibrium between the ACE-AngII-AT1R and ACE2-Ang (1-7)-MasR axes is implicated in PHSML-mediated AKI."

Journal • Preclinical • Acute Kidney Injury • Hematological Disorders • Nephrology • Renal Disease • ACE2

Impact of antihypertensive treatment on cardiovascular event reduction in patients with asymptomatic carotid artery stenosis: a systematic review and meta-analysis. (PubMed, Pan Afr Med J) - "The results reported that enalapril and fosinopril demonstrated dual benefits in blood pressure (BP) reduction and vascular remodeling, though meta-analysis showed statistically insignificant improvements in regional cerebral blood flow (CI: -0.84, 6.08, P = 0.14, I2= 94%). Similarly, isradipine, lacidipine, and amlodipine improved carotid hemodynamics and cerebral perfusion, with meta-analysis favoring calcium channel blocker intervention for blood pressure management (CI: -3.25 to 7.64, P = 0.43)...Moreover, beta-blockers showed specific benefits, with metoprolol improving plaque echogenicity (57.3 ± 16.8 vs. 51.8 ± 20.0, p = 0.006) and reducing cardiovascular events (17% vs. 37% placebo, p = 0.011), while labetalol effectively managed post-endarterectomy hypertension. In conclusion, antihypertensive treatments showed varying effectiveness in cardiovascular event reduction and improvements in vessel measures."

Clinical • Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Hypertension

Association Between Common Systemic Medications and the Presence and Severity of Furcation Involvement: A Cross-Sectional Study. (PubMed, Healthcare (Basel)) - "The use of certain systemic medications, particularly for cardiovascular conditions, is independently associated with both a higher likelihood and increased severity of furcation involvement, highlighting the critical need for dental professionals to consider a patient's medication profile as an integral part of periodontal risk assessment."

Journal • Observational data • Cardiovascular • Dental Disorders • Periodontitis

Agonist Antibody to Natriuretic Peptide Receptor 1 for CKD (KIDNEY WEEK 2025) - "The addition of empagliflozin to REGN5381 plus enalapril further improved survival and reduced albuminuria. In the RKM model of CKD, REGN5381 reduced albuminuria, and improved kidney histopathology and cardiac ejection fraction, indicating that the benefits of REGN5381 are not limited to AS. Conclusion NPR1 agonism with REGN5381 benefited the kidney and heart in multiple CKD models, presenting a potential novel therapeutic strategy to treat CKD."

Chronic Kidney Disease • Fibrosis • Genetic Disorders • Immunology • Inflammation • Nephrology • Renal Disease

An exploratory evaluation of the interaction risk between herbal products and pharmaceutical medicines used concurrently for disease management in Blantyre, Malawi. (PubMed, Pharm Biol) - "Participants reported concurrent use of a wide variety of herbal products (e.g., garlic, ginger, okra, lemon, mango, moringa) with prescription medicines (e.g., metformin, insulin, glibenclamide, hydrochlorothiazide, enalapril, amlodipine). This study provides foundational data on herbal-pharmaceutical co-use in Malawi and highlights the need for expanded research, improved documentation of herbal use in healthcare settings, and improved education for patients and providers. Integrating awareness of herbal product use into clinical care is essential, and the methodology and findings may inform future hypothesis-driven studies across Africa and other regions where traditional and modern medicine use overlaps."

Journal • Cardiovascular • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders

A QSPR study of coronary artery disease drugs using eccentricity-based indices. (PubMed, Sci Rep) - "This study advances QSPR modeling by using eccentricity-based graphical invariants, specifically designed to enhance the predictive accuracy for physicochemical properties of drugs used to treat coronary artery disease, including atorvastatin, simvastatin, rosuvastatin, aspirin, clopidogrel, metoprolol, atenolol, enalapril, lisinopril, amlodipine, diltiazem, nitroglycerin, isosorbide dinitrate, ranolazine, gemfibrozil, and fenofibrate. The experimental values were compared with forecasted data, revealing a strong correlation between them. This demonstrates the reliability of our regression models in assessing these vital physicochemical parameters."

Journal • Cardiovascular • Coronary Artery Disease

Breast cancer progression in the presence of treated and untreated left ventricular dysfunction. (PubMed, Cardiooncology) - "Specific HF treatments can mitigate cancer growth in a mouse model of MI-induced LV dysfunction, with outcomes varying by treatment. These benefits occurred only with LV dysfunction, suggesting they result from changes in HF pathophysiology rather than direct drug effects on tumor cells. Restoration of immune signaling may contribute to these effects."

Journal • Breast Cancer • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Oncology • Solid Tumor • IFNG • STAT1

Dense Deposit Disease in Adults: Recognizing and Managing a Rare Glomerulopathy (KIDNEY WEEK 2025) - "Initial management included Diuretics, ACE inhibitor (Enalapril), and a Statin...The patient was started on prednisone (1 mg/kg) which resulted to partial reduction in proteinuria and resolution of symptoms...This case highlights the importance of early recognition and timely renal biopsy in patients with atypical or refractory nephrotic syndrome. Multidisciplinary care and individualized management remain essential to improve outcomes in this rare and complex glomerulopathy."

Clinical • Chronic Kidney Disease • Complement-mediated Rare Disorders • Dyslipidemia • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease

ALECT2 Amyloid Concurrent with IgAN (KIDNEY WEEK 2025) - "Case Description A 49-year old Hispanic female diagnosed with IgAN had been managed on conservative therapy with enalapril and spironolactone with stable serum creatinine (Cr) of 1.1-1.2mg/dL and proteinuria (UPCR) of ~1g/g...A 45-year old Hispanic female diagnosed with IgAN had been managed on losartan with stable serum Cr at 1.7mg/dL...Treatment is supportive as no current therapies exist. These cases demonstrate the need for consideration of other pathologies that could be contributing to worsening renal function especially in Hispanic patients with IgAN as it could impact future management."

Amyloidosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

Secondary FSGS and Control of Proteinuria with Cyclosporine: A Case Report (KIDNEY WEEK 2025) - "Prednisone was initiated in 2019 and gradually tapered...The patient remained asymptomatic and adhered to dietary sodium restriction, weight management, and continued enalapril...The patient’s response supports the consideration of cyclosporine in secondary FSGS, with careful monitoring. This case highlights the importance of individualized treatment and the need for further studies on CNIs and genetic contributions in secondary FSGS."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Hypertension • Nephrology • Obesity • Renal Disease

Crescentic Phase of Alport Syndrome: A Rare Glimpse into Rapid Progression (KIDNEY WEEK 2025) - "His hyperkalemia was medically managed without stopping enalapril...Given its rarity, it is unclear whether this entity should be treated different than non-crescentic Alport syndrome. Native kidney biopsy specimen demonstrating glomerulus with mesangial expansion, mesangial hypercellularity, and an early fibrocelluar crescent by light microscopy with Periodic acid–Schiff stain."

Chronic Kidney Disease • Fibrosis • Genetic Disorders • Glomerulonephritis • Immunology • Lupus Nephritis • Nephrology • Otorhinolaryngology • Pediatrics • Renal Disease • COL4A5

Dengue Virus Infection as a Trigger for Collapsing Glomerulopathy in a Patient with an APOL1 High-Risk Genotype (KIDNEY WEEK 2025) - "She was on use of hydroxyurea, enalapril and folic acid...The patient started on hemodialysis and has been treated with pulse of methylprednisolone 500 mg for 3 days, followed by prednisone 80 mg and mycophenolate 2 g/day. One month after treatment start, the patient improved renal function, and was discharged from hospital with an eGFR 20ml/min/1.73m 2 Discussion Viral infections are frequent triggers for GC in patients with APOL1-HRG. In tropical countries, arboviruses such as DENV, Zika and Chikungunya should also be investigated in patients with GC, especially if they carry APOL1-HRG."

Clinical • Anemia • Cardiovascular • Chikungunya • Chronic Kidney Disease • Dengue Fever • Fibrosis • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Sickle Cell Disease

Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline-Targeted Therapy. (PubMed, Health Sci Rep) - "Of the 292 study participants, 209 (71.6%) were on ACEIs, with Enalapril being the only drug in use...Although the majority of patients were receiving ACEIs, only a small proportion of these were using optimal dosages. Therefore, a multidisciplinary team approach that includes clinical pharmacists in the medication review and patient monitoring processes would achieve definite outcomes in patients with HF."

Journal • Observational data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders

ANSWER-HF: A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction (AHA 2025) - P3 | "In patients with CCC and HFrEF, sacubitril-valsartan did not result in significant improvements in LVEF compared with enalapril after 6 months, but was associated with a greater reduction in NT-proBNP. There were no safety concerns associated with either sacubitril-valsartan or enalapril in this population. These findings provide high quality evidence about the efficacy and safety of sacubitril-valsartan and enalapril in HFrEF due to CCC and may help physicians in the decision-making process when treating this high-risk group of patients."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Changes in hepatic and renal Doppler ultrasonography: Current standard therapy in dogs with congestive heart failure. (PubMed, Open Vet J) - "As a current standard therapy, pimobendan, enalapril, and furosemide were administered to dogs for 4 weeks. Doppler ultrasonography findings demonstrated that heart failure worsens the vascular hemodynamics of the kidney and liver in dogs. Congestive heart failure treatment may improve the cardiorenal and cardiohepatic changes due to CHF."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

The Influence of pH and Preservative Agents on Physicochemical and Microbiological Stability of a Flexible Dose/Age-Appropriate Formulation of Enalapril Maleate. A Quality by Design‑Based Optimization. (PubMed, AAPS PharmSciTech) - "Chemical stability of ENA showed variation depending on the specific formulation conditions and the influence of pH, buffer type, preservative agent, and storage temperature on the stability of the active ingredient was determined by DoE. The final selected formulation: enalapril 2 mg mL-1, pH 3.5, containing 10% v/v glycerin, 10 mM citrate buffer, and 0.2% w/v sodium benzoate, demonstrated to be physically, chemically, and microbiologically stable for at least six months under refrigerated conditions, with drug recoveries exceeding 95%, and a robust Design Space was established for its manufacture and storage."

Journal • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hypertension • Pediatrics

A green HPLC-UV method for the simultaneous analysis of enalapril, enalaprilat and diketopiperazine in pharmaceutical formulations. (PubMed, Anal Methods) - "Relative to the official method, the optimised procedure shortened the chromatographic run by approximately 8 minutes, reduced organic solvent consumption by 17.1 mL (equivalent to US$ 0.40) per run, and achieved better scores in the NEMI, GAPI, Eco-Scale (84 vs. 89), and AGREE (0.57 vs. 0.78) assessment tools. During validation, the linear range for enalapril was established as 140-260 μg mL-1, and the method proved capable of simultaneously quantifying enalapril, enalaprilat, and diketopiperazine with BAGI and RAPI scores of 80.0 and 67.5, respectively."

Journal

Targeting asparagine and cysteine in SARS-CoV-2 variants and human pro-inflammatory mediators to alleviate COVID-19 severity; a cross-section and in-silico study. (PubMed, Sci Rep) - "During the early pandemic, the IL-6 inhibitor (tocilizumab) was the widely used approved immunotherapy for critically ill patients; however, a subset of ICU cases exhibited normal interleukin-6 (IL-6) levels and failed to respond...Several phytochemicals, including phytic acid and amygdalin, as well as synthetic agents such as candesartan, remdesivir, and enalapril, were found to preferentially bind to cysteine (Cys) residues-and, to a lesser extent, asparagine (Asn) residues-within key binding interfaces, in addition to targeting B-cell epitopes...This dual-perspective approach not only identified IL-17 and IL-6 as independent severity predictors but also revealed conserved Asn and Cys motifs as critical therapeutic targets, leading to novel strategies-such as ASNase, synthetic agents and phytochemical combinations-for simultaneously blocking viral entry and modulating hyperinflammatory pathways. These findings warrant rigorous experimental and clinical validation to..."

Biomarker • IO biomarker • Journal • Hematological Disorders • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IL17A • IL6R • ITGA2B • ITGB3 • SIRPA

Apical Hypertrophic Cardiomyopathy: Diagnostic Challenges in a Patient with Hypertension and Obstructive Sleep Apnea. (PubMed, Am J Case Rep) - "His medical history included longstanding hypertension managed with atenolol and enalapril, and untreated OSA. CONCLUSIONS ApHCM should be considered in patients with dyspnea, hypertension, and OSA when giant precordial T-wave inversions are present. ECG and MRI confirming apical hypertrophy without outflow obstruction guide medical therapy, not septal reduction, and prioritize blood pressure optimization, OSA treatment, ambulatory rhythm monitoring, and structured follow-up to mitigate adverse outcomes."

Journal • Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy • Obstructive Sleep Apnea • Pain • Pulmonary Disease • Respiratory Diseases • Sleep Disorder